Gloria Pharmaceuticals

Gloria Pharmaceuticals, established in March 2000, is a high-tech enterprise group with a main focus on the pharmaceuticals and broader health industry. Its core business lies in pharmaceutical production, encompassing research, manufacturing, and marketing. Since its listing in 2010 (stock code: 002437), Gloria Pharmaceuticals has adhered to a "product leadership" strategy. Through external mergers and acquisitions, collaboration and agency partnerships, independent research and development, and overseas product introductions, the company has diversified its product portfolio. It expanded from an initially narrow focus on orthopedic treatments to now include major therapeutic areas such as cardiovascular and cerebrovascular treatments. This resulted in several key product clusters across fields like cardiovascular and cerebrovascular care, musculoskeletal health, and nutritional medications. A new growth pattern driven by multiple products has gradually emerged. With lofty ambitions and relentless efforts, Gloria Pharmaceuticals has progressively built an integrated modern pharmaceuticals supply chain meeting various standards, ensuring drug quality at every stage from R&D, formulation production, to market operations. The company has established multiple modern pharmaceutical production bases in Harbin, Datong, Qidong, and other locations, all certified under China’s Good Manufacturing Practice (GMP) standards. Additionally, it has developed a marketing system compliant with Good Supply Practice (GSP). Gloria Pharmaceuticals continues to advance product innovation aligned with international standards, deepen business model innovation tailored to China’s national conditions, and promote a tripartite governance mechanism of “products, mechanisms, and talent.” It actively secures, optimizes, and allocates resources while expanding into innovative sectors such as CMO platforms, biopharmaceutical R&D, and chronic disease-focused product services.